<DOC>
	<DOCNO>NCT00605241</DOCNO>
	<brief_summary>GSK598809 develop innovative treatment substance dependence potentially compulsive behavioral disorder . This study asses effect single dose GSK598809 modulate nicotine reward 2 cohort otherwise healthy male volunteer smoke . Each cohort subject receive single dose placebo GSK598809 two dose session bind crossover fashine . There washout period least seven day session .</brief_summary>
	<brief_title>A Study To Assess The Effects Of A Single Dose Of GSK598809 In Modulating Nicotine Reward</brief_title>
	<detailed_description />
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy male smoker age 1865 desire quit smoking . Body weight great 50kg BMI within range 19 29.9 kg/m2 Healthy significant medical , psychiatric laboratory evaluation abnormality . Positive prestudy urine drug/breath alcohol screen : positive HIV 1/2 , Hepatitis B Hepatitis C test screening . History alcohol/drug abuse dependence ( nicotine ) within 12 month study . History psychiatric disorder sensitivity study medication component thereof history drug allergy opinion physician responsible contraindicates participation . History cardiac pulmonary disease/abnormalities .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pharmacodynamics ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>tolerability ,</keyword>
	<keyword>Safety ,</keyword>
	<keyword>single dose ,</keyword>
	<keyword>placebo ,</keyword>
	<keyword>Nicotine reward</keyword>
	<keyword>GSK598809</keyword>
</DOC>